Antivirals and neutralising monoclonal antibodies in the treatment of Covid-19 in hospitalised Patients

A COVID-19 therapeutic alert has been issued: neutralising monoclonal antibodies (nMABs) and antivirals for treatment of Covid-19 hospitalised patients.

The policy has been updated to reflect the withdrawal of the casirivimab and  imdevimab (Ronapreve) neutralising monoclonal antibody (nMAB) combination as a  treatment option for patients hospitalised due to symptoms of COVID-19.

Further information and actions can be found in the COVID-19 therapeutic alert and interim clinical commissioning policy on the CAS alert website